GWM
PRQR icon

Geneos Wealth Management’s ProQR Therapeutics PRQR Stock Holding History

Geneos Wealth Management’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,000
Closed -$1.3K – 2157
2023
Q3 		$1.3K Buy
+1,000
New +$1.57K ﹤0.01% 1992

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Geneos Wealth Management's PRQR Position: Q4 2023 in Review

Geneos Wealth Management sold out of ProQR Therapeutics (PRQR) in Q4 2023, closing a stake of 1,000 shares — an estimated $1.3K sold.

Geneos Wealth Management first reported a position in PRQR in Q3 2023 and held it in 1 quarter. The position peaked at $1.3K in Q3 2023. 47 funds tracked by Wall St. Rank hold PRQR as of Q4 2023.

  • Geneos Wealth Management reported no remaining ProQR Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Geneos Wealth Management sold 1,000 ProQR Therapeutics shares in Q4 2023, an estimated $1.3K.
  • Geneos Wealth Management first reported a position in ProQR Therapeutics in Q3 2023 and held it in 1 quarter.
  • Geneos Wealth Management's ProQR Therapeutics position peaked at $1.3K in Q3 2023.
  • 47 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q4 2023.

Based on Geneos Wealth Management's 13F filing for Q4 2023, filed 26 Jan 2024.